KIEV, February 8. /TASS/. The situation with the spread of the coronavirus in Ukraine has stabilized: the average weekly incidence indicators decreased three-fold, Ukrainian President Vladimir Zelensky said at the "Ukraine 30. Coronavirus: Challenges and Answers" forum on Monday.
"We managed to attain stabilization with the spread of the coronavirus and to decrease three-fold the average weekly number of infections," the head of state said.
According to him, now Ukraine faces new tasks in the fight against the coronavirus. "First of all - inoculation and its road map," he noted, stressing the need to provide equal access to vaccines for residents. "The main task is to involve [in vaccination] no less than half of population during 2021 and the beginning of 2022," he emphasized.
According to him, another priority is the readiness of Ukraine’s medical infrastructure for challenges. "We need to create a new monitoring system of biological threats, including studying the spread of pathogens in animal world which bear a risk of spreading to humans," the president explained.
Over the past 24 hours, Ukrainian medics have recorded 2,141 cases of the coronavirus infection which is 36% less than the figures of the previous day when the daily growth amounted to 3,370. The total number of infections during the pandemic in the country has reached 1,246,990, with 1,075,743 recoveries and 23,644 fatalities.
The vaccination in Ukraine has not started yet. The country refused to use the Russian Sputnik V preparation and is conducting talks with other manufacturers. At the end of last year, an agreement was concluded for the delivery of over 1.9 mln doses of a vaccine against the coronavirus by China's Sinovac Biotech; the first 700,000 doses should arrive in February. Ukraine also expects supplies of vaccines through the COVAX program under the auspices of the World Health Organization: in mid-February the country will receive 117,000 doses of a vaccine by Pfizer. In February, Kiev also hopes to receive 12 mln doses of preparations by AstraZeneca and Novavax.